When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
EYEG - Aimmune's PDUFA Jitters And Other News: The Good Bad And Ugly Of Biopharma
Eyegate Pharmaceuticals Inc.
Aimmune Therapeutics, Inc. (AIMT) has been quite a sprightly stock lately, and it has a couple of key events coming up as well. However, the firm also faces a few obstacles, the foremost being the FDA's stepmotherly attitude over the years. Its lead drug candidate Palforzia was approved by the FDA advisory committee with 7 to 2 votes for its efficacy. The same committee voted 8 to 1 establishing the safety of the drug. However, since this positive event in September last year, the FDA has not moved forward, causing concern for AIMT investors.